Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Pancreatic Cancer
  •  Gastrointestinal Cancer
  •  Paediatric Cancers
  •  Radiation Oncology
  •  Targeted Therapy
  •  Chemoprevention
  •  Lymphoma
  •  Stomach Cancer


Citation: Clin Oncol. 2023;8(1):2028.DOI: 10.25107/2474-1663.2028

Differential Expression of PP2A and Set in Hepatocellular Carcinoma: Antitumoral Effect of an Interfering Peptide Blocking the Interaction

Rachid Boudjelloul, Angelita Rebollo, Severine Loisel, Frederic Charlotte, Jean Francois Franetich and Eric Savier

UTCBS, Inserm U1267, Faculty of Pharmacy, Paris Cite University, Paris, France Common Animal Shop, University of Brest, F-29238 Brest, France
Department of Pathological Anatomy, Public Assistance - Paris Hospitals, Pitié Salpêtrière, Paris, France
Cimi, Faculty of Medicine, Sorbonne University, France
Department of Hepato-Bilio-Pancreatic Surgery, Liver Transplantation, Public Assistance - Paris Hospitals, Pitié Salpêtrière, Sorbonne University, Paris, France
Saint Antoine Research Center, Sorbonne University, Inserm, Paris, France

*Correspondance to: Angelita Rebollo 

 PDF  Full Text Research Article | Open Access


Hepatocellular carcinoma is one of the most frequent cancers worldwide. Systemic treatments such as immune checkpoint or tyrosine kinase inhibitors have some efficacy but also have many adverse effects. More specifically targeted therapies are therefore needed. In this study, we investigated the anti-tumoral effect of a tumor penetrating and interfering peptide blocking the interaction between the proteins PP2A and SET. We analyzed the expression of two proteins, the phosphatase PP2A and the oncoprotein SET, in a group of samples from 21 liver cancer patients with different aggressiveness scores. Expression of PP2Aand SET was found to correlate with aggressiveness of the tumor. In vivo tests on xenograft models of hepatocellular carcinoma xenograft models showed an anti-tumoral effect of iRGD-IP, a tumor-penetrating and interfering peptide that blocks PP2A/ SET interaction and specifically targets tumor cells suggesting that this peptide could be a strong candidate for development as therapeutic peptide for liver tumor treatment.


Therapeutic peptide; Liver cancer; Xenograft models; PP2A; SET

Cite the Article:

Boudjelloul R, Rebollo A, Loisel S, Charlotte F, Franetich JF, Savier E. Differential Expression of PP2A and Set in Hepatocellular Carcinoma: Antitumoral Effect of an Interfering Peptide Blocking the Interaction. Clin Oncol. 2023;8:2028..

Search Our Journal

Journal Indexed In

Articles in PubMed

NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

CEA and CA19-9 Levels and KRAS Mutation Status as Biomarkers for Colorectal Cancer
 Abstract  PDF  Full Text
NLRP3 Inflammasome Enhances Tumor Growth
 Abstract  PDF  Full Text
View More...